This is a clinical trial designed to examine how improved sleep through morning bright light therapy is improving downstream key physiologic processes related to brain health, i.e., mitochondrial function, systemic inflammation, and glymphatic function. All proposed methodology is already approved in other IRB applications.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
300
Exposure to bright light shortly after waking.
Exposure to negative ions shortly after waking.
Oregon Health and Science University
Portland, Oregon, United States
RECRUITINGDefine the profile of blood-based markers of systemic inflammation pre- vs post-MBLT.
The primary outcome defines the pre- to post-intervention change in inflammatory target expression using NULISA proteomics (reporting proteins as NPQ relative units).
Time frame: From pre-intervention to end of device use (Approximately 4 weeks).
Define mitochondrial function (oxygen consumption rate via Seahorse) pre- vs. post-MBLT.
The primary outcome of this aim reflects pre- to post-intervention change in mitochondrial bioenergetics. Specific metrics include basal oxygen consumption rate, maximal oxygen consumption rate, and spare/reserve capacity (difference between maximal and basal oxygen consumption rate).
Time frame: From pre-intervention to end of device use (Approximately 4 weeks).
Explore glymphatic function via novel multi-model non-contrast-based MRI pre- vs. post-MBLT.
The primary outcome defines pre- to post-intervention change in MRI visibler perivascular space burden (PVS number/volume).
Time frame: From pre-intervention to end of device use (Approximately 4 weeks).
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.